SPRAVATO® (esketamine) CIII nasal spray is a newly FDA-approved medication for treatment-resistant depression. It is the first and only antidepressant approved for this indication that works in a completely new way. Unlike traditional antidepressants, which can take weeks or even months to start working, SPRAVATO® begins to work within hours. In addition, it has been shown to be effective in patients who have not responded to other treatments.
Adults with treatment-resistant depression (TRD)
Depressive symptoms in adults with major depressive disorder (MDD) with suicidal thoughts or actions
Some of the potential side effects associated with SPRAVATO® are nausea, vomiting, diarrhea, dizziness, headache, and temporary changes in blood pressure and heart rate. All patients who are taking SPRAVATO® are closely monitored by our staff who will adjust the dosage as needed to minimize side effects.
Have blood vessel (aneurysmal vascular) disease (including in the brain, chest, abdominal aorta, arms and legs)
Have an abnormal connection between your veins and arteries (arteriovenous malformation)
Have a history of bleeding in the brain
Are allergic to esketamine, ketamine, or any of the other ingredients in SPRAVATO®.
SPRAVATO® (esketamine) CIII nasal spray, is the first and only FDA-approved treatment shown to significantly reduce depressive symptoms within two days in people who haven't responded to other medications. The active ingredient in SPRAVATO®, esketamine, belongs to a class of medicines called NMDA receptor antagonists. It works differently than most currently available antidepressants, which target the monoaminergic system.